SAGE Therapeutics (SAGE) Tops Q1 EPS by 27c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to SAGE Therapeutics (SAGE) Tops Q1 EPS by 27c, Revenues Miss

Sage Therapeutics (SAGE) PT Lowered to $84 at RBC Capital Following Earnings

May 4, 2021 12:52 PM EDT

RBC Capital analyst Brian Abrahams lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $84.00 (from $89.00) while maintaining a Sector Perform rating following results.

The analyst commented, "This morning, SAGE reported 1Q21 earnings and guided for $1.7B in cash by end-'21, for a burn rate of... More